Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Identification of Novel Molecular Targets for the Development of Therapies in Patients With Rheumatoid Arthritis Responsive to Disease-modifying Antirheumatic (DMARDs) But Wirh Progressive Bone Erosion (AREOS)

NCT04201535 is registered in ClinicalTrials.gov with I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio as lead sponsor.

NCT NCT04201535
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201535 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Identification of Novel Molecular Targets for the Development of Therapies in Patients With Rheumatoid Arthritis Responsive to Disease-modifying Antirheumatic (DMARDs) But Wirh Progressive Bone Erosion (AREOS)
Lead sponsor
I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio
Phase
Observational
Overall status
Unknown status
Start date
December 21, 2017
Completion date
June 30, 2021
Enrollment
160 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

arthritis, rheumatoid, bone erosion